1	The	The	B-NP	DT	O	5	NMOD	0
2	tyrosine	tyrosine	I-NP	NN	B-protein	5	NMOD	0
3	kinase	kinase	I-NP	NN	I-protein	5	NMOD	0
4	inhibitor	inhibitor	I-NP	NN	O	5	NMOD	0
5	cediranib	cediranib	I-NP	NN	O	6	SUB	0
6	blocks	block	B-VP	VBZ	O	0	ROOT	18	blocks
7	ligand-induced	ligand-induced	B-NP	JJ	B-protein	12	NMOD	17	induced
8	vascular	vascular	I-NP	JJ	I-protein	12	NMOD	0
9	endothelial	endothelial	I-NP	JJ	I-protein	12	NMOD	0
10	growth	growth	I-NP	NN	I-protein	12	NMOD	0
11	factor	factor	I-NP	NN	I-protein	12	NMOD	0
12	receptor-3	receptor-3	I-NP	NN	I-protein	15	NMOD	0
13	activity	activity	I-NP	NN	O	15	NMOD	0
14	and	and	I-NP	CC	O	15	NMOD	0
15	lymphangiogenesis	lymphangiogenesis	I-NP	NN	O	6	OBJ	0
16	.	.	O	.	O	6	P	0

1	Solid	Solid	B-NP	JJ	O	2	NMOD	0
2	tumors	tumor	I-NP	NNS	O	3	SUB	0
3	express	express	B-VP	VBP	O	0	ROOT	0
4	a	a	B-NP	DT	O	5	NMOD	0
5	range	range	I-NP	NN	O	3	OBJ	0
6	of	of	B-PP	IN	O	5	NMOD	0
7	factors	factor	B-NP	NNS	O	6	PMOD	0
8	required	require	B-VP	VBN	O	7	NMOD	0
9	to	to	B-VP	TO	O	10	VMOD	0
10	sustain	sustain	I-VP	VB	O	8	VMOD	0
11	their	their	B-NP	PRP$	O	12	NMOD	0
12	growth	growth	I-NP	NN	O	10	OBJ	0
13	and	and	O	CC	O	3	VMOD	0
14	promote	promote	B-VP	VBP	O	3	VMOD	0
15	their	their	B-NP	PRP$	O	16	NMOD	0
16	dissemination	dissemination	I-NP	NN	O	14	OBJ	0
17	.	.	O	.	O	3	P	0

1	Among	Among	B-PP	IN	O	3	PRD	0
2	these	these	B-NP	DT	O	3	SUB	0
3	are	be	B-VP	VBP	O	0	ROOT	0
4	vascular	vascular	B-NP	JJ	B-protein	7	NMOD	0
5	endothelial	endothelial	I-NP	JJ	I-protein	7	NMOD	0
6	growth	growth	I-NP	NN	I-protein	7	NMOD	0
7	factor-A	factor-A	I-NP	NN	I-protein	22	NMOD	0
8	(	(	O	(	O	10	DEP	0
9	VEGF-A	VEGF-A	B-NP	NN	B-protein	10	DEP	0
10	)	)	O	)	O	7	NMOD	0
11	,	,	O	,	O	22	P	0
12	the	the	B-NP	DT	O	15	NMOD	0
13	key	key	I-NP	JJ	O	15	NMOD	0
14	angiogenic	angiogenic	I-NP	JJ	O	15	NMOD	3	angiogenic
15	stimulant	stimulant	I-NP	NN	O	22	NMOD	0
16	,	,	O	,	O	22	P	0
17	and	and	O	CC	O	22	NMOD	0
18	VEGF-C	VEGF-C	B-NP	NN	B-protein	22	NMOD	0
19	,	,	O	,	O	22	P	0
20	a	a	B-NP	DT	O	22	NMOD	0
21	primary	primary	I-NP	JJ	O	22	NMOD	0
22	mediator	mediator	I-NP	NN	O	3	PRD	0
23	of	of	B-PP	IN	O	22	NMOD	0
24	lymphangiogenesis	lymphangiogenesis	B-NP	NN	O	23	PMOD	0
25	.	.	O	.	O	3	P	0

1	Small	Small	B-NP	JJ	O	5	NMOD	0
2	molecule	molecule	I-NP	NN	O	5	NMOD	0
3	tyrosine	tyrosine	I-NP	NN	O	5	NMOD	0
4	kinase	kinase	I-NP	NN	O	5	NMOD	0
5	inhibitors	inhibitor	I-NP	NNS	O	6	SUB	0
6	offer	offer	B-VP	VBP	O	0	ROOT	0
7	the	the	B-NP	DT	O	8	NMOD	0
8	potential	potential	I-NP	NN	O	6	OBJ	0
9	to	to	B-VP	TO	O	10	VMOD	0
10	inhibit	inhibit	I-VP	VB	O	8	NMOD	0
11	more	more	B-NP	JJR	O	12	AMOD	0
12	than	than	I-NP	IN	O	14	NMOD	0
13	one	one	I-NP	CD	O	12	AMOD	0
14	kinase	kinase	I-NP	NN	O	10	OBJ	0
15	and	and	O	CC	O	6	VMOD	0
16	impede	impede	B-VP	VBP	O	6	VMOD	18	impede
17	tumor	tumor	B-NP	NN	O	18	NMOD	0
18	growth	growth	I-NP	NN	O	16	OBJ	4	growth
19	by	by	B-PP	IN	O	6	VMOD	0
20	multiple	multiple	B-NP	JJ	O	21	NMOD	0
21	mechanisms	mechanism	I-NP	NNS	O	19	PMOD	0
22	.	.	O	.	O	6	P	0

1	However	However	B-ADVP	RB	O	8	VMOD	0
2	,	,	O	,	O	8	P	0
3	their	their	B-NP	PRP$	O	4	NMOD	0
4	potency	potency	I-NP	NN	O	8	SUB	0
5	toward	toward	B-PP	IN	O	4	NMOD	0
6	individual	individual	B-NP	JJ	O	7	NMOD	0
7	targets	target	I-NP	NNS	O	5	PMOD	0
8	can	can	B-VP	MD	O	0	ROOT	0
9	vary	vary	I-VP	VB	O	8	VC	0
10	.	.	O	.	O	8	P	0

1	Cediranib	Cediranib	B-NP	NN	O	7	SUB	0
2	(	(	O	(	O	6	DEP	0
3	RECENTIN	RECENTIN	B-NP	NN	O	5	NMOD	0
4	;	;	O	:	O	5	P	0
5	AZD2171	AZD2171	B-NP	NN	O	6	DEP	0
6	)	)	O	)	O	1	NMOD	0
7	is	be	B-VP	VBZ	O	46	VMOD	0
8	an	an	B-NP	DT	O	9	NMOD	0
9	inhibitor	inhibitor	I-NP	NN	O	7	PRD	0
10	of	of	B-PP	IN	O	9	NMOD	0
11	VEGF	VEGF	B-NP	NN	B-protein	12	NMOD	0
12	signaling	signaling	I-NP	NN	O	10	PMOD	0
13	that	that	B-NP	WDT	O	9	NMOD	0
14	has	have	B-VP	VBZ	O	13	SBAR	0
15	been	be	I-VP	VBN	O	14	VC	0
16	shown	show	I-VP	VBN	O	15	VC	0
17	in	in	B-PP	IN	O	16	VMOD	0
18	experimental	experimental	B-NP	JJ	O	19	NMOD	0
19	models	model	I-NP	NNS	O	17	PMOD	0
20	to	to	B-VP	TO	O	21	VMOD	0
21	prevent	prevent	I-VP	VB	O	16	VMOD	18	prevent
22	VEGF-A-induced	VEGF-A-induced	B-NP	JJ	O	23	NMOD	17	induced
23	angiogenesis	angiogenesis	I-NP	NN	O	27	NMOD	3	angiogenesis
24	and	and	O	CC	O	27	NMOD	0
25	primary	primary	B-NP	JJ	O	27	NMOD	0
26	tumor	tumor	I-NP	NN	O	27	NMOD	0
27	growth	growth	I-NP	NN	O	21	OBJ	4	growth
28	,	,	O	,	O	46	P	0
29	yet	yet	O	RB	O	31	NMOD	0
30	the	the	B-NP	DT	O	31	NMOD	0
31	effects	effect	I-NP	NNS	O	46	SUB	16	effects
32	of	of	B-PP	IN	O	31	NMOD	0
33	cediranib	cediranib	B-NP	NN	O	32	PMOD	0
34	on	on	B-PP	IN	O	31	NMOD	0
35	VEGF	VEGF	B-NP	NN	B-protein	43	NMOD	0
36	receptor	receptor	I-NP	NN	I-protein	43	NMOD	0
37	(	(	I-NP	(	O	39	DEP	0
38	VEGFR	VEGFR	I-NP	NN	B-protein	39	DEP	0
39	)	)	I-NP	)	O	43	NMOD	0
40	-3-mediated	-3-mediated	I-NP	JJ	O	43	NMOD	16	mediated
41	endothelial	endothelial	I-NP	JJ	O	43	NMOD	0
42	cell	cell	I-NP	NN	O	43	NMOD	0
43	function	function	I-NP	NN	O	45	NMOD	0
44	and	and	I-NP	CC	O	45	NMOD	0
45	lymphangiogenesis	lymphangiogenesis	I-NP	NN	O	34	PMOD	0
46	are	be	B-VP	VBP	O	0	ROOT	0
47	unknown	unknown	B-ADJP	JJ	O	46	PRD	0
48	.	.	O	.	O	46	P	0

1	To	To	B-VP	TO	O	3	VMOD	0
2	better	well	I-VP	RBR	O	3	VMOD	0
3	understand	understand	I-VP	VB	O	23	VMOD	0
4	the	the	B-NP	DT	O	5	NMOD	0
5	activity	activity	I-NP	NN	O	14	NMOD	0
6	of	of	B-PP	IN	O	5	NMOD	0
7	cediranib	cediranib	B-NP	NN	O	6	PMOD	0
8	against	against	B-PP	IN	O	7	NMOD	0
9	VEGFR-3	VEGFR-3	B-NP	NN	B-protein	8	PMOD	0
10	and	and	O	CC	O	14	NMOD	0
11	its	its	B-NP	PRP$	O	14	NMOD	0
12	associated	associate	I-NP	VBN	O	14	NMOD	0
13	signaling	signaling	I-NP	NN	O	14	NMOD	0
14	events	event	I-NP	NNS	O	3	OBJ	0
15	compared	compare	B-PP	VBN	O	14	NMOD	0
16	with	with	B-PP	IN	O	15	PMOD	0
17	its	its	B-NP	PRP$	O	18	NMOD	0
18	activity	activity	I-NP	NN	O	16	PMOD	0
19	against	against	B-PP	IN	O	18	NMOD	0
20	VEGFR-2	VEGFR-2	B-NP	NN	B-protein	19	PMOD	0
21	,	,	O	,	O	23	P	0
22	we	we	B-NP	PRP	O	23	SUB	0
23	used	use	B-VP	VBD	O	0	ROOT	0
24	the	the	B-NP	DT	O	26	NMOD	0
25	receptor-specific	receptor-specific	I-NP	JJ	O	26	NMOD	0
26	ligands	ligand	I-NP	NNS	O	29	NMOD	0
27	VEGF-E	VEGF-E	I-NP	NN	O	29	NMOD	0
28	and	and	I-NP	CC	O	29	NMOD	0
29	VEGF-C156S	VEGF-C156S	I-NP	NN	O	23	OBJ	0
30	.	.	O	.	O	23	P	0

1	In	In	B-PP	IN	O	7	VMOD	0
2	human	human	B-NP	JJ	B-cell_type	4	NMOD	0
3	endothelial	endothelial	I-NP	JJ	I-cell_type	4	NMOD	0
4	cells	cell	I-NP	NNS	I-cell_type	1	PMOD	0
5	,	,	O	,	O	7	P	0
6	cediranib	cediranib	B-NP	NN	O	7	SUB	0
7	inhibited	inhibit	B-VP	VBD	O	0	ROOT	18	inhibited
8	VEGF-E-induced	VEGF-E-induced	B-NP	JJ	O	9	NMOD	17	induced
9	phosphorylation	phosphorylation	I-NP	NN	O	7	OBJ	12	phosphorylation
10	of	of	B-PP	IN	O	9	NMOD	0
11	VEGFR-2	VEGFR-2	B-NP	NN	B-protein	14	NMOD	0
12	and	and	O	CC	O	14	NMOD	0
13	VEGF-C156S-induced	VEGF-C156S-induced	B-NP	JJ	O	14	NMOD	17	induced
14	phosphorylation	phosphorylation	I-NP	NN	O	10	PMOD	12	phosphorylation
15	of	of	B-PP	IN	O	14	NMOD	0
16	VEGFR-3	VEGFR-3	B-NP	NN	B-protein	15	PMOD	0
17	at	at	B-PP	IN	O	7	VMOD	0
18	concentrations	concentration	B-NP	NNS	O	17	PMOD	0
19	of	of	B-PP	IN	O	18	NMOD	0
20	less	less	B-NP	JJR	O	19	PMOD	0
21	than	than	B-PP	IN	O	20	AMOD	0
22	/=1nmol/L	/=1nmol/L	B-NP	NN	B-protein	21	PMOD	0
23	and	and	O	CC	O	7	VMOD	0
24	inhibited	inhibit	B-VP	VBD	O	7	VMOD	0
25	activation	activation	B-NP	NN	O	24	OBJ	0
26	of	of	B-PP	IN	O	25	NMOD	0
27	downstream	downstream	B-NP	JJ	B-protein	29	NMOD	0
28	signaling	signal	I-NP	VBG	I-protein	29	NMOD	0
29	molecules	molecule	I-NP	NNS	I-protein	26	PMOD	0
30	.	.	O	.	O	7	P	0

1	Additionally	Additionally	B-ADVP	RB	O	4	VMOD	0
2	,	,	O	,	O	4	P	0
3	cediranib	cediranib	B-NP	NN	O	4	SUB	0
4	blocked	block	B-VP	VBD	O	0	ROOT	18	blocked
5	VEGF-C156S-induced	VEGF-C156S-induced	B-NP	JJ	O	7	AMOD	17	induced
6	and	and	I-NP	CC	O	7	AMOD	0
7	VEGF-E-induced	VEGF-E-induced	I-NP	JJ	O	8	NMOD	17	induced
8	proliferation	proliferation	I-NP	NN	O	13	NMOD	1	proliferation
9	,	,	O	,	O	13	P	0
10	survival	survival	B-NP	NN	O	13	NMOD	5	survival
11	,	,	O	,	O	13	P	0
12	and	and	O	CC	O	13	NMOD	0
13	migration	migration	B-NP	NN	O	4	OBJ	14	migration
14	of	of	B-PP	IN	O	13	NMOD	0
15	lymphatic	lymphatic	B-NP	JJ	B-cell_type	20	NMOD	0
16	and	and	I-NP	CC	I-cell_type	20	NMOD	0
17	blood	blood	I-NP	NN	I-cell_type	20	NMOD	0
18	vascular	vascular	I-NP	JJ	I-cell_type	20	NMOD	0
19	endothelial	endothelial	I-NP	JJ	I-cell_type	20	NMOD	0
20	cells	cell	I-NP	NNS	I-cell_type	14	PMOD	0
21	.	.	O	.	O	4	P	0

1	In	In	B-ADVP	FW	O	9	VMOD	0
2	vivo	vivo	I-ADVP	FW	O	1	AMOD	0
3	,	,	O	,	O	9	P	0
4	cediranib	cediranib	B-NP	NN	O	9	SUB	0
5	(	(	O	(	O	8	DEP	0
6	6	6	B-NP	CD	O	7	NMOD	0
7	mg/kg/d	mg/kg/d	I-NP	NN	O	8	DEP	0
8	)	)	O	)	O	4	NMOD	0
9	prevented	prevent	B-VP	VBD	O	0	ROOT	18	prevented
10	angiogenesis	angiogenesis	B-NP	NN	O	12	NMOD	3	angiogenesis
11	and	and	I-NP	CC	O	12	NMOD	0
12	lymphangiogenesis	lymphangiogenesis	I-NP	NN	O	9	OBJ	0
13	induced	induce	B-VP	VBN	O	12	NMOD	17	induced
14	by	by	B-PP	IN	O	13	VMOD	0
15	VEGF-E-expressing	VEGF-E-expressing	B-NP	JJ	O	18	NMOD	9	expressing
16	and	and	I-NP	CC	O	18	NMOD	0
17	VEGF-C156S-expressing	VEGF-C156S-expressing	I-NP	JJ	O	18	NMOD	9	expressing
18	adenoviruses	adenovirus	I-NP	NNS	O	14	PMOD	0
19	,	,	O	,	O	9	P	0
20	respectively	respectively	B-ADVP	RB	O	9	VMOD	0
21	.	.	O	.	O	9	P	0

1	Cediranib	Cediranib	B-NP	NN	O	7	SUB	0
2	(	(	O	(	O	5	DEP	0
3	6	6	B-NP	CD	O	4	NMOD	0
4	mg/kg/day	mg/kg/day	I-NP	NN	O	5	DEP	0
5	)	)	O	)	O	1	NMOD	0
6	also	also	B-ADVP	RB	O	7	VMOD	0
7	blocked	block	B-VP	VBD	O	0	ROOT	18	blocked
8	angiogenesis	angiogenesis	B-NP	NN	O	10	NMOD	3	angiogenesis
9	and	and	I-NP	CC	O	10	NMOD	0
10	lymphangiogenesis	lymphangiogenesis	I-NP	NN	O	7	OBJ	0
11	induced	induce	B-VP	VBN	O	10	NMOD	0
12	by	by	B-PP	IN	O	11	VMOD	0
13	adenoviruses	adenovirus	B-NP	NNS	O	12	PMOD	0
14	expressing	express	B-VP	VBG	O	13	NMOD	9	expressing
15	VEGF-A	VEGF-A	B-NP	NN	B-protein	17	NMOD	0
16	or	or	I-NP	CC	O	17	NMOD	0
17	VEGF-C	VEGF-C	I-NP	NN	O	14	OBJ	0
18	and	and	O	CC	O	7	VMOD	0
19	compromised	compromise	B-VP	VBD	O	7	VMOD	0
20	the	the	B-NP	DT	O	24	NMOD	0
21	blood	blood	I-NP	NN	O	24	NMOD	0
22	and	and	O	CC	O	24	NMOD	0
23	lymphatic	lymphatic	B-NP	JJ	O	24	NMOD	0
24	vasculatures	vasculature	I-NP	NNS	O	19	OBJ	0
25	of	of	B-PP	IN	O	24	NMOD	0
26	VEGF-C-expressing	VEGF-C-expressing	B-NP	JJ	O	27	NMOD	9	expressing
27	tumors	tumor	I-NP	NNS	O	25	PMOD	0
28	.	.	O	.	O	7	P	0

1	Cediranib	Cediranib	B-NP	NN	O	2	SUB	0
2	may	may	B-VP	MD	O	0	ROOT	0
3	,	,	O	,	O	2	P	0
4	therefore	therefore	B-ADVP	RB	O	2	VMOD	0
5	,	,	O	,	O	2	P	0
6	be	be	B-VP	VB	O	2	VC	0
7	an	an	B-NP	DT	O	9	NMOD	0
8	effective	effective	I-NP	JJ	O	9	NMOD	0
9	means	mean	I-NP	NNS	O	6	PRD	0
10	of	of	B-PP	IN	O	9	NMOD	0
11	preventing	prevent	B-VP	VBG	O	10	PMOD	18	preventing
12	tumor	tumor	B-NP	NN	O	13	NMOD	0
13	progression	progression	I-NP	NN	O	11	OBJ	2	progression
14	,	,	O	,	O	15	P	0
15	not	not	B-CONJP	RB	O	13	NMOD	0
16	only	only	I-CONJP	RB	O	15	DEP	0
17	by	by	B-PP	IN	O	15	PMOD	0
18	inhibiting	inhibit	B-VP	VBG	O	17	PMOD	18	inhibiting
19	VEGFR-2	VEGFR-2	B-NP	NN	B-protein	20	NMOD	0
20	activity	activity	I-NP	NN	O	22	NMOD	0
21	and	and	O	CC	O	22	NMOD	0
22	angiogenesis	angiogenesis	B-NP	NN	O	18	OBJ	3	angiogenesis
23	,	,	O	,	O	22	NMOD	0
24	but	but	B-CONJP	CC	O	23	PMOD	0
25	also	also	I-CONJP	RB	O	24	DEP	0
26	by	by	B-PP	IN	O	24	PMOD	0
27	concomitantly	concomitantly	B-NP	RB	O	28	AMOD	0
28	inhibiting	inhibit	I-NP	VBG	O	26	PMOD	18	inhibiting
29	VEGFR-3	VEGFR-3	I-NP	NN	B-protein	30	NMOD	0
30	activity	activity	I-NP	NN	O	32	NMOD	0
31	and	and	I-NP	CC	O	32	NMOD	0
32	lymphangiogenesis	lymphangiogenesis	I-NP	NN	O	28	OBJ	0
33	.	.	O	.	O	2	P	0

